Study of E7389 for Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate
the safety of patients who continue to receive E7389 after completing the Phase II clinical
study (E7389-J081-221; hereafter referred to as Study 221) of E7389 for advanced or relapsed
breast cancer by intravenously administering E7389.